U.S. markets closed

Senseonics Holdings, Inc. (SENS)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
3.0200-0.0500 (-1.63%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.0700
Open3.0700
Bid3.0000 x 1800
Ask3.0200 x 4000
Day's Range2.9600 - 3.0900
52 Week Range0.3500 - 5.5600
Volume6,006,456
Avg. Volume29,266,361
Market Cap1.293B
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    Better Meme Stock: Clover Health or Senseonics Holdings?

    Both Clover Health Investments (NASDAQ: CLOV) and Senseonics Holdings (NYSEMKT: SENS) have emerged as meme stocks over the last few months. Senseonics has been the much bigger winner so far, but that doesn't necessarily mean it will continue to outperform Clover Health going forward. In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these two meme stocks is the better pick right now.

  • Why Senseonics Skyrocketed 340% in the First Half of 2021
    Motley Fool

    Why Senseonics Skyrocketed 340% in the First Half of 2021

    Shares of Senseonics Holdings (NYSEMKT: SENS) skyrocketed 340% in the first half of 2021. One key early catalyst for Senseonics was a positive coverage decision in January by health insurer EmblemHealth for the Eversense continuous glucose-monitoring (CGM) system used by individuals with diabetes. In June, Senseonics reported positive results from a clinical study of its version of the Eversense device that can remain implanted for 180 days.

  • Senseonics Biggest Supporters Have Got to Be Patient
    InvestorPlace

    Senseonics Biggest Supporters Have Got to Be Patient

    Senseonics Holdings (NYSEAMERICAN:SENS) has been on a hot streak the past month. After going sideways for three months, SENS stock took off at the beginning of June. As I write this, it’s up more than 72% over the past 30 days. Source: Shutterstock If it keeps up this pace, it could be out of penny-stock status in no time. In my last article about the maker of glucose-monitoring products at the end of April, I honed in on the company’s accumulated deficit as a red flag for risk-averse investors.